Atypical Hemolytic Uremic Syndrome Associated with BNT162b2 mRNA COVID-19 Vaccine in a Kidney Transplant Recipient: A Case Report and Literature Review

被引:0
|
作者
Pattonieri, Eleonora Francesca [1 ]
Gregorini, Marilena [1 ,2 ]
Grignano, Maria Antonietta [1 ]
Islami, Tefik [1 ]
D'Ambrosio, Gioacchino [3 ,4 ]
Ardissino, Gianluigi [5 ]
Rampino, Teresa [1 ,2 ]
机构
[1] Fdn IRCCS Policlin San Matteo, Unit Nephrol Dialysis & Transplants, I-27100 Pavia, Italy
[2] Univ Pavia, Dept Internal Med & Therapeut, I-27100 Pavia, Italy
[3] Univ Pavia, Dept Mol Med, Anat Pathol Unit, I-27100 Pavia, Italy
[4] Fdn IRCCS Policlin San Matteo, I-27100 Pavia, Italy
[5] Fdn IRCCS CaGranda Osped Maggiore Policlin, Ctr HUS Prevent Control & Management, I-20162 Milan, Italy
关键词
BNT162b2; COVID-19; vaccination; hemolytic uremic syndrome; acute kidney injury; kidney transplant;
D O I
10.3390/idr17010014
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Case Report: We report a case of a 37-year-old female with kidney transplant, who was admitted at our hospital due to worsening renal function, nephrotic proteinuria, and anemia developed 21 days after the second dose of BNT162b2 COVID-19 vaccine (Pfizer-BioNTech). Laboratory tests revealed hemolytic anemia, thrombocytopenia, and acute kidney injury. Given the clinical picture of Thrombotic Micro-angiopathy (TMA) and severe renal impairment, plasma exchange (PEX) and dialysis were immediately started. Laboratory workup showed low C3 and C4 levels, normal activity of ADAMTS13, and the absence of anti-factor H antibodies. Molecular biology investigations revealed a heterozygous variant in exon 22 (SCR20) of the CFH gene (c.3628C>T; p.Arg1210Cys) described as an atypical Hemolytic Uremic Syndrome (aHUS) causative mutation. Our patient completed two sessions of PEX followed by eculizumab treatment with hematological improvement but no recovery of renal function. This is the first reported case of aHUS triggered by SARS-CoV-2 vaccination in a kidney transplant patient without recovery of renal function. Conclusion: Although rare, clinicians should be aware of possible nephrological complications that may appear after vaccination.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Acute cervical dystonia following the BNT162b2 mRNA COVID-19 vaccine
    Algahtani, Hussein A.
    Shirah, Bader H.
    Alwafi, Emad
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2022, 218
  • [22] Batch-dependent safety of the BNT162b2 mRNA COVID-19 vaccine
    del Saz, Borja Somovilla
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2023, 53 (12)
  • [23] Platelet and immune signature associated with a rapid response to the BNT162b2 mRNA COVID-19 vaccine
    Flego, Davide
    Cesaroni, Simone
    Romiti, Giulio F.
    Corica, Bernadette
    Marrapodi, Ramona
    Scafa, Noemi
    Maiorca, Francesca
    Lombardi, Ludovica
    Pallucci, Davide
    Pulcinelli, Fabio
    Raparelli, Valeria
    Visentini, Marcella
    Cangemi, Roberto
    Piconese, Silvia
    Alvaro, Domenico
    Polimeni, Antonella
    Basili, Stefania
    Stefanini, Lucia
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2022, 20 (04) : 961 - 974
  • [24] Posterior ocular manifestations following BNT162b2 mRNA COVID-19 vaccine: a case series
    Pillar, Shani
    Weinberg, Tamar
    Amer, Radgonde
    INTERNATIONAL OPHTHALMOLOGY, 2023, 43 (05) : 1677 - 1686
  • [25] Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis
    Magen, Eli
    Mukherjee, Sumit
    Bhattacharya, Mahua
    Detroja, Rajesh
    Merzon, Eugene
    Blum, Idan
    Livoff, Alejandro
    Shlapobersky, Mark
    Baum, Gideon
    Talisman, Ran
    Cherniavsky, Evgenia
    Dori, Amir
    Frenkel-Morgenstern, Milana
    VACCINES, 2022, 10 (07)
  • [26] Upper extremity deep venous thrombosis after BNT162b2 mRNA COVID-19 vaccine case report
    Gonzalez, Susan
    Levine, David M. M.
    CLINICAL CASE REPORTS, 2023, 11 (02):
  • [27] Posterior ocular manifestations following BNT162b2 mRNA COVID-19 vaccine: a case series
    Shani Pillar
    Tamar Weinberg
    Radgonde Amer
    International Ophthalmology, 2023, 43 : 1677 - 1686
  • [28] BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity
    Vizcarra, Pilar
    Haemmerle, Johannes
    Velasco, Hector
    Velasco, Tamara
    Fernandez-Escribano, Marina
    Vallejo, Alejandro
    Casado, Jose L.
    VACCINE, 2021, 39 (51) : 7367 - 7374
  • [29] Safety and Immunogenicity of a Single Dose of BNT162b2 COVID-19 mRNA Vaccine in a Warfarin-Treated Protein S Deficient Patient: A Case Report and Literature Review
    Cucunawangsih, Cucunawangsih
    Wijaya, Ratna Sari
    Lugito, Nata Pratama Hardjo
    Suriapranata, Ivet
    HEMATOLOGY REPORTS, 2022, 14 (04) : 373 - 376
  • [30] New-onset systemic lupus erythematosus following BNT162b2 mRNA COVID-19 vaccine: a case series and literature review
    Sagy, Iftach
    Zeller, Lior
    Raviv, Yael
    Porges, Tzvika
    Bieber, Amir
    Abu-Shakra, Mahmoud
    RHEUMATOLOGY INTERNATIONAL, 2022, 42 (12) : 2261 - 2266